^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

urabrelimab (SRF231)

i
Other names: SRF231, SRF-231, SRF 231
Company:
Coherus Biosci
Drug class:
CD47 inhibitor
over4years
[VIRTUAL] SRF231, a fully human CD47 antibody, potentiates the effects of opsonizing antibodies and cytotoxic chemotherapies in preclinical cancer models (AACR-II 2020)
Enhanced ADCP was observed with SRF231 in combination with opsonizing antibodies elotuzumab (anti-SLAMF7) and daratumumab (anti-CD38)...Cisplatin monotherapy induced modest H1975 anti-tumor activity; however, combination with SRF231 potentiated the effect of cisplatin in this model. Additionally, combination of SRF231 with docetaxel resulted in a 45% CR rate and a significant delay in H1975 tumor regrowth, as compared to a 100% regrowth rate with docetaxel monotherapy.In summary, SRF231 demonstrated significant anti-tumor activity in combination with the anti-SLAMF7 opsonizing antibody, elotuzumab, in preclinical MM xenograft models. Moreover, SRF231 potentiated the effects of taxane and platinum-based standard of care chemotherapies in preclinical NSCLC xenograft models. These results offer further guidance on the clinical development of anti-CD47 modalities in cancer treatment.
Preclinical • IO biomarker
|
EGFR (Epidermal growth factor receptor) • CD38 (CD38 Molecule) • FCGR2A (Fc fragment of IgG receptor IIa)
|
EGFR mutation • EGFR H1975
|
cisplatin • docetaxel • Darzalex (daratumumab) • Empliciti (elotuzumab) • urabrelimab (SRF231)